PCN52 ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX,) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
Abstract
Authors
D Greenberg M Rabinovich M Hirsch